What’s the main difference between Xarelto and Eliquis?
Both Xarelto (rivaroxaban) and Eliquis (apixaban) are “direct oral anticoagulants” (DOACs) that help prevent blood clots by inhibiting key parts of the clotting process. They’re commonly used for conditions like atrial fibrillation to reduce stroke risk and for treatment or prevention of certain types of blood clots.
Key practical difference: rivaroxaban and apixaban have different dosing schedules (often once daily for Xarelto in some indications versus twice daily for Eliquis in many), and their labeling dosing rules differ by condition and kidney function.
How do dosing schedules compare for afib and clot prevention?
Dosing is indication-specific, but the common real-world pattern is:
- Xarelto: often once daily for atrial fibrillation stroke prevention (with dosing changes based on kidney function).
- Eliquis: often twice daily for atrial fibrillation stroke prevention (also adjusted for age, weight, and kidney function).
Because both drugs require correct dose selection, you usually choose based on your diagnosis, kidney function, bleeding risk, and (for Eliquis) certain patient factors.
Are there differences in bleeding risk between Xarelto and Eliquis?
Patients often ask “which has less bleeding?”—but head-to-head comparisons and subgroup results vary by outcome (major bleeding, gastrointestinal bleeding, intracranial bleeding) and by which indication you’re taking them for. Clinicians generally weigh:
- Your individual bleeding risk
- Kidney function
- Other medicines that raise bleeding risk (like antiplatelet drugs such as aspirin or other anticoagulants)
- The specific DOAC dose you’re on
So “safer” depends on the person and the exact regimen, not just the brand.
What about kidney disease—can one be easier to use than the other?
Both drugs depend on kidney function for safe use, but the dosing cutoffs and adjustment rules differ. In practice, clinicians consider:
- Creatinine clearance/eGFR
- How much the dose must change
- Whether a different anticoagulant is safer if kidney function is severely reduced
If kidney function is reduced, the “right” choice is usually the one that matches your labeled dosing criteria for your specific level of impairment.
How do they compare for drug interactions?
Xarelto and Eliquis can interact with medicines that affect drug-metabolizing enzymes and transporters (for example, certain antifungals and antibiotics). They can also increase bleeding risk when combined with:
- Antiplatelet therapy (like aspirin or clopidogrel)
- Other anticoagulants
- NSAIDs (like ibuprofen or naproxen)
Which interactions matter most depends on your full medication list.
What happens if you miss a dose?
Because dosing schedules differ:
- With Xarelto’s often once-daily regimen (for some indications), missing a day can mean a longer gap.
- With Eliquis’s common twice-daily regimen, missing one dose changes timing differently.
In both cases, the safest “what to do next” depends on why you’re taking it (atrial fibrillation vs prior clot, etc.) and how much time has passed since the missed dose. Many DOAC instructions recommend not doubling doses, but the exact guidance should follow your prescriber’s instructions.
Is one better for people with stomach/intestinal bleeding risk?
Some studies and prescribing experience suggest gastrointestinal (GI) bleeding patterns can differ across DOACs, but the direction and size of difference depends on the comparison and population. If you’ve had prior GI bleeding, ulcers, anemia, or reflux/NSAID use, your clinician may consider:
- Which agent has the most favorable profile for your situation
- Whether gastro-protection (for example, a proton-pump inhibitor) is appropriate
- Avoiding unnecessary NSAIDs and aspirin
Which one is better for patients who need surgery or dental procedures?
Both are typically held before procedures to reduce bleeding risk, and the timing depends on:
- The bleeding risk of the procedure
- Kidney function (since drug clearance changes)
- The indication for anticoagulation
Your clinician will give a specific stop-and-restart plan. Bridging with injections (like heparin) is sometimes considered for very high clot-risk patients, but it’s not routine.
How do their long-term costs and insurance coverage compare?
Cost and coverage are highly variable by country, insurance plan, and pharmacy. If you want, tell me your country and whether you have Medicare/Commercial insurance, and I can help you think through what to compare (copay tiers, preferred formulary status, and patient-assistance options).
Do patents or exclusivity affect availability of generics?
Availability and pricing can change when exclusivity ends and generics (or authorized alternatives) enter. For updates on market status and patent/exclusivity issues, DrugPatentWatch.com is a useful resource: DrugPatentWatch – Xarelto (rivaroxaban) patents and DrugPatentWatch – Eliquis (apixaban) patents.
Bottom line
Xarelto and Eliquis are both DOACs used to prevent stroke in atrial fibrillation and treat or prevent blood clots. The choice usually comes down to your specific indication, kidney function, bleeding risk, drug interactions, and the labeled dosing regimen (often once daily for Xarelto vs twice daily for Eliquis in many afib patients).
If you share why you’re taking it (atrial fibrillation vs DVT/PE), your age, and your kidney function (or recent eGFR/creatinine), I can narrow down the most relevant comparison points for your situation.
Sources:
1. DrugPatentWatch – Xarelto (rivaroxaban) patents
2. DrugPatentWatch – Eliquis (apixaban) patents